We are live on ! Find out more
FENC icon

Fennec Pharmaceuticals
FENC

56 hedge funds and large institutions have $125M invested in Fennec Pharmaceuticals in 2023 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 18 increasing their positions, 11 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $1.11M | Put options by funds: $362K

64% more repeat investments, than reductions

Existing positions increased: 18 | Existing positions reduced: 11

18% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 17

15% more capital invested

Capital invested by funds: $108M → $125M (+$16M)

6% more funds holding

Funds holding: 53 → 56 (+3)

4.02% more ownership

Funds ownership: 49.31% → 53.34% (+4%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
56
Holders Change
+3
Holders Change %
+5.66%
% of All Funds
0.88%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
20
Increased
18
Reduced
11
Closed
17
Calls
$1.11M
Puts
$362K
Net Calls
+$748K
Net Calls Change
-$448K

Top Buyers

1
BlackRock
BlackRock
New York
+$6.47M
2
State Street
State Street
Massachusetts
+$2.17M
3
ACM
AIGH Capital Management
Maryland
+$1.56M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.47M
5
SCM
Solas Capital Management
Connecticut
+$1.28M

Top Sellers

1
DCM
DG Capital Management
New York
-$1.46M
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.25M
3
TA
Tamarack Advisers
California
-$1.24M
4
Millennium Management
Millennium Management
New York
-$858K
5
1CM
1492 Capital Management
Wisconsin
-$789K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
1
Southpoint Capital Advisors
New York
$36M – – –
SGL
2
Sonic GP LLC
Hawaii
$21.3M – – –
SCM
3
Solas Capital Management
Connecticut
$12.7M +$1.28M +154,485 +12%
ACA
4
Avoro Capital Advisors
New York
$10.6M – – –
DCM
5
DG Capital Management
New York
$9.49M -$1.46M -175,442 -14%
BlackRock
6
BlackRock
New York
$7.33M +$6.47M +778,481 +1,508%
HFA
7
Harbert Fund Advisors
Alabama
$4.12M – – –
ACM
8
AIGH Capital Management
Maryland
$3.09M +$1.56M +187,303 +116%
6CM
9
683 Capital Management
New York
$2.65M – – –
GJL
10
Gendell Jeffrey L
$2.5M +$259K +31,127 +12%
State Street
11
State Street
Massachusetts
$2.31M +$2.17M +261,485 New
Geode Capital Management
12
Geode Capital Management
Massachusetts
$1.74M +$1.47M +177,370 +909%
Northern Trust
13
Northern Trust
Illinois
$1.01M +$952K +114,483 New
LPC
14
Lion Point Capital
New York
$971K +$915K +110,000 New
WVP
15
Worth Venture Partners
New Jersey
$823K +$398K +47,814 +105%
ACA
16
Apis Capital Advisors
New York
$795K – – –
Millennium Management
17
Millennium Management
New York
$766K -$858K -103,204 -54%
CIBC World Market
18
CIBC World Market
Ontario, Canada
$711K -$286K -34,363 -30%
Vanguard Group
19
Vanguard Group
Pennsylvania
$705K +$664K +79,873 New
Morgan Stanley
20
Morgan Stanley
New York
$536K +$20.7K +2,485 +4%
HFM
21
Hartford Financial Management
Connecticut
$400K +$33.3K +4,000 +10%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$399K +$376K +45,242 New
Charles Schwab
23
Charles Schwab
California
$366K +$345K +41,497 New
Citadel Advisors
24
Citadel Advisors
Florida
$347K +$33.7K +4,056 +11%
N
25
Nuveen
North Carolina
$304K +$203K +24,461 New
1
2 3

FENC Hedge Fund Activity: Q2 2023 in Review

56 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q2 2023, worth a combined $125M — up 15% from $108M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new FENC positions and 17 closed out — a net gain of 3 holders — while 18 added to existing stakes and 11 trimmed.

The largest buyer was BlackRock, adding an estimated $6.47M. The largest seller was DG Capital Management, cutting an estimated $1.46M.

  • 56 institutional investors held Fennec Pharmaceuticals (FENC) as of Q2 2023, up from 53 in Q1 2023.
  • Funds reported $125M of Fennec Pharmaceuticals stock for Q2 2023, up 15% quarter-over-quarter.
  • 20 funds opened new Fennec Pharmaceuticals positions in Q2 2023 and 17 closed out, a net change of +3 holders.
  • The largest Fennec Pharmaceuticals buyer in Q2 2023 was BlackRock, an estimated $6.47M added.
  • The largest Fennec Pharmaceuticals seller in Q2 2023 was DG Capital Management, an estimated $1.46M sold.

Based on aggregated 13F filings for Q2 2023.